LRFN5 and OLFM4 in Acute Manic Episodes With Psychotic Features in Bipolar Disorder: A Case-Control Study in Türkiye

Mehmet Hamdi Örüm1, Seda Yılmaz2, Pınar Öner3

  • 1Psychiatry Clinic, Elazığ Mental Health and Diseases Hospital, Elazığ, Türkiye.

Insights

Individuals with bipolar disorder (BD) experiencing manic episodes with psychosis have lower serum levels of leucine-rich repeat and fibronectin type III domain-containing protein-5 (LRFN5) and olfactomedin-4 (OLFM4). Higher aggregate index of systemic inflammation (AISI) correlates with BD status and symptom severity.

Area of Science:

  • Neuroscience
  • Psychiatry
  • Biochemistry

Background:

  • Bipolar disorder (BD) is a complex psychiatric condition.
  • Systemic inflammation and specific protein levels may be implicated in BD pathophysiology.
  • Understanding biomarkers associated with manic episodes is crucial for diagnosis and treatment.

Purpose of the Study:

  • To compare serum levels of leucine-rich repeat and fibronectin type III domain-containing protein-5 (LRFN5) and olfactomedin-4 (OLFM4), and aggregate index of systemic inflammation (AISI) in patients with BD experiencing acute manic episodes with psychotic features versus healthy controls (HCs).
  • To investigate the association of these markers with clinical features and symptom severity in BD patients.

Main Methods:

  • Cross-sectional study design.
  • Serum LRFN5 and OLFM4 levels measured via Enzyme-Linked ImmunoSorbent Assay.
  • AISI calculated and compared between BD (n=37) and HC (n=35) groups.
  • Clinical features assessed using structured clinical interviews.
  • Statistical analyses included adjusted comparisons, correlation, and binary logistic regression.

Main Results:

  • Significantly lower serum LRFN5 and OLFM4 levels in the BD group compared to HCs (adjusted P=0.0117 for both).
  • Significantly higher AISI levels in the BD group compared to HCs (adjusted P=0.0005).
  • LRFN5 and OLFM4 showed a strong positive correlation within the BD group (r=0.702, adjusted P=0.006).
  • AISI positively correlated with manic symptom severity (r=0.472, adjusted P=0.030).
  • Lower OLFM4 (OR=0.970, adjusted P=0.003) and higher AISI (OR=1.008, adjusted P=0.001) were independently associated with BD status.

Conclusions:

  • Individuals with BD experiencing acute manic episodes with psychotic features exhibit reduced circulating LRFN5 and OLFM4 levels.
  • An increased systemic inflammatory burden, indicated by AISI, is associated with BD.
  • AISI demonstrated the strongest association with BD status and symptom severity.
  • These findings may reflect underlying biological processes in BD rather than serving as definitive diagnostic markers.

Related Concept Videos

Mania and Antimanic Drugs: Overview01:24

Mania and Antimanic Drugs: Overview

Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
800
Bipolar Disorder01:30

Bipolar Disorder

Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
1.4K
Psychosis: Goals of Pharmacotherapy01:26

Psychosis: Goals of Pharmacotherapy

Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
706
Psychosis and Antipsychotic Drugs: Overview01:28

Psychosis and Antipsychotic Drugs: Overview

The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
1.2K